Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules.
Injection of fluorescein intravenously for fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0.05%). A serious reaction may occur without warning in a patient with no history of atopy. There are no reports of oral fluorescein causing a serious reaction, and minor adverse effects are uncommon. A study was undertaken to determine optimum conditions for oral fluorescein angiography. Capsules proved more convenient than a solution for ingestion of fluorescein. A dose of 25 mg/kg body weight produced good quality angiograms in 75% of the patients. The best pictures were obtained by photographing the fundus after 40 and 60 minutes.
Watson
A P
AP
District General Hospital, Southport, Merseyside.
Rosen
E S
ES
D000284:Administration, Oral; D002214:Capsules; D019793:Fluorescein; D005451:Fluorescein Angiography / Q000009:adverse effects / Q000379:methods*; D005452:Fluoresceins / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D013673:Technology Assessment, Biomedical
D002214:Capsules; D005452:Fluoresceins; D019793:Fluorescein